# Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease

> **NCT01616680** · PHASE2 · WITHDRAWN · sponsor: **Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium**

## Conditions studied

- Graft Versus Host Disease

## Interventions

- **DRUG:** brentuximab vedotin
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT01616680
- **Lead sponsor:** Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-09
- **Primary completion:** 2016-06
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01616680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01616680, "Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01616680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*